Liver abnormalities in connective tissue diseases

Best Practice and Research: Clinical Gastroenterology

Volumn 27, Issue 4, 2013, Pages 543-551

  De Santis, Maria ^a,b   Crotti, Chiara ^a   Selmi, Carlo ^a,b,c  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoimmune liver disease; Systemic lupus erythematosus; Viral hepatitis

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ACETYLSALICYLIC ACID; AZATHIOPRINE; BELIMUMAB; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; RITUXIMAB; SALICYLIC ACID; STEROID;

ANTIPHOSPHOLIPID SYNDROME; ANTISYNTHETASE SYNDROME; ARTICLE; AUTOIMMUNE HEPATITIS; BUDD CHIARI SYNDROME; CHOLESTASIS; CONNECTIVE TISSUE DISEASE; DERMATOMYOSITIS; FATTY LIVER; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FUNCTION TEST; LIVER HYPERPLASIA; LIVER INJURY; LIVER TOXICITY; POLYMYOSITIS; PORTAL HYPERTENSION; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; VIRUS HEPATITIS; VIRUS REACTIVATION; VIRUS RELEASE;

EID: 84885183658     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2013.06.016     Document Type: Review

References (70)

1. Selmi C, Mackay IR, Gershwin ME. The immunological milieu of the liver. Semin Liver Dis 2007;27:129-39 (Pubitemid 46871659)
2. Youssef WI, Tavill AS. Connective tissue diseases and the liver. J Clin Gastroenterol 2002;35:345-9
3. Runyon BA, LaBrecque DR, Anuras S. The spectrum of liver disease in systemic lupus erythematosus. Report of 33 histologically-proved cases and review of the literature. Am J Med 1980;69:187-94 (Pubitemid 10036815)
4. Ohira H, Takiguchi J, Rai T, Abe K, Yokokawa J, Sato Y, et al. High frequency of anti-ribosomal P antibody in patients with systemic lupus erythematosus-associated hepatitis. Hepatol Res. 2004;28:137-9 (Pubitemid 38220222)
5. Matsumoto T, Yoshimine T, Shimouchi K, Shiotu H, Kuwabara N, Fukuda Y, et al. The liver in systemic lupus erythematosus: pathologic analysis of 52 cases and review of Japanese Autopsy Registry Data. Hum Pathol 1992;23:1151-8
6. Chowdhary VR, Crowson CS, Poterucha JJ, Moder KG. Liver involvement in systemic lupus erythematosus: case review of 40 patients. J Rheumatol 2008;35:2159-64
7. Abraham S, Begum S, Isenberg D. Hepatic manifestations of autoimmune rheumatic diseases. Ann Rheum Dis 2004;63: 123-9 (Pubitemid 38124506)
8. Efe C, Ozaslan E, Nasiroglu N, Tunca H, Purnak T, Altiparmak E. The development of autoimmune hepatitis and primary biliary cirrhosis overlap syndrome during the course of connective tissue diseases: report of three cases and review of the literature. Dig Dis Sci. 2010;55:2417-21
9. Schlenker C, Halterman T, Kowdley KV. Rheumatologic disease and the liver. Clin Liver Dis 2011;15:153-64
10. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990;11:272-6
11. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993;46:1331-6 (Pubitemid 23333874)
12. Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997;26:664-9 (Pubitemid 27392358)
13. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45 (Pubitemid 12149145)
14. Dart RC, Green JL, Kuffner EK, Heard K, Sproule B, Brands B. The effects of paracetamol (acetaminophen) on hepatic tests in patients who chronically abuse alcohol-a randomized study. Aliment Pharmacol Ther 2010;32:478-86
15. Seaman WE, Ishak KG, Plotz PH. Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus. Ann Intern Med 1974;80:1-8
16. Miller MH, Urowitz MB, Gladman DD, Blendis LM. The liver in systemic lupus erythematosus. Q J Med 1984;53:401-9 (Pubitemid 14004820)
17. Cohen-Ezra O, Avni Y, Morgenstern S, Ben-Ari Z [Nodular regenerative hyperplasia as a complication of thiopurine treatment in a patient with inflammatory bowel disease]. Harefuah 2012;151:675-8. 721
18. Goldberg JW, Lidsky MD. Cyclophosphamide-associated hepatotoxicity. South Med J 1985;78:222-3 (Pubitemid 15130360)
19. Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology (Oxford) 2012;51(Suppl 5):v38-47
20. Zouali M, Uy EA. Belimumab therapy in systemic lupus erythematosus. BioDrugs 2013;27:225-35
21. Hahn BH. Belimumab for systemic lupus erythematosus. N Engl J Med 2013;368:1528-35
22. Pomeroy C, Knodell RG, Swaim WR, Arneson P, Mahowald ML. Budd-Chiari syndrome in a patient with the lupus anticoagulant. Gastroenterology 1984;86:158-61 (Pubitemid 14177331)
23. Vergani D, Longhi MS, Bogdanos DP, Ma Y, Mieli-Vergani G. Autoimmune hepatitis. Semin Immunopathol 2009;31: 421-35
24. Raszeja-Wyszomirska J, Miezynska-Kurtycz J, Marlicz W, Lawniczak M, Wojcicki M. Primary Budd-Chiari syndrome-a single center experience. Hepatogastroenterology 2012;59:1879-82
25. Aggarwal R, Ravishankar B, Misra R, Aggarwal A, Dwivedi S, Naik SR. Significance of elevated IgG anticardiolipin antibody levels in patients with Budd-Chiari syndrome. Am J Gastroenterol 1998;93:954-7 (Pubitemid 29076985)
26. Uthman I, Khamashta M. The abdominal manifestations of the antiphospholipid syndrome. Rheumatology (Oxford) 2007; 46:1641-7 (Pubitemid 350018483)
27. Villamil A, Sorkin E, Basta MC, Mysler E, Macias S, Pekolj J, et al. Catastrophic antiphospholipid syndrome complicating orthotopic liver transplantation. Lupus 2003;12:140-3 (Pubitemid 36240849)
28. Guiu B, Loffroy R, Cercueil JP, Sagot P, Krause D, Tixier H. MRI diagnosis and follow-up of hepatic infarction in a patient with antiphospholipid syndrome in early pregnancy. Arch Gynecol Obstet 2011;283:659-62
29. Gologorsky E, Andrews DM, Gologorsky A, Sampathi V, Sundararaman L, Govindaswamy R, et al. Devastating intracardiac and aortic thrombosis: a case report of apparent catastrophic antiphospholipid syndrome during liver transplantation. J Clin Anesth 2011;23:398-402
30. Collier JD, Sale J, Friend PJ, Jamieson NV, Calne RY, Alexander GJ. Graft loss and the antiphospholipid syndrome following liver transplantation. J Hepatol 1998;29:999-1003 (Pubitemid 28559072)
31. Bayraktar Y, Tanaci N, Egesel T, Gokoz A, Balkanci F. Antiphospholipid syndrome presenting as portopulmonary hypertension. J Clin Gastroenterol 2001;32:359-61 (Pubitemid 32231737)
32. Klein R, Goller S, Bianchi L. Nodular regenerative hyperplasia (NRH) of the liver-a manifestation of ?organ-specific antiphospholipid syndrome Immunobiology 2003;207:51-7 (Pubitemid 36285097)
33. Perney P, Biron-Andreani C, Joomaye Z, Fabbro-Peray P, Quenet F, Schved JF, et al. Antiphospholipid antibodies in alcoholic liver disease are influenced by histological damage but not by alcohol consumption. Lupus 2000;9:451-5 (Pubitemid 30487429)
34. Zachou K, Liaskos C, Rigopoulou E, Gabeta S, Papamichalis P, Gatselis N, et al. Presence of high avidity anticardiolipin antibodies in patients with autoimmune cholestatic liver diseases. Clin Immunol 2006;119:203-12
35. Tincani A, Andreoli L, Cavazzana I, Doria A, Favero M, Fenini MG, et al. Novel aspects of Sjogren?s syndrome in 2012. BMC Med 2013;11:93
36. Kaplan MJ, Ike RW. The liver is a common non-exocrine target in primary Sjogren?s syndrome: a retrospective review. BMC Gastroenterol 2002;2:21
37. Kita H, Naidenko OV, Kronenberg M, Ansari AA, Rogers P, He XS, et al. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology 2002;123:1031-43
38. Chiorini JA, Cihakova D, Ouellette CE, Caturegli P. Sjogren syndrome: advances in the pathogenesis from animal models. J Autoimmun 2009;33:190-6
39. Strand V, Talal N. Advances in the diagnosis and concept of Sjogren?s syndrome (autoimmune exocrinopathy). Bull Rheum Dis 1979;30:1046-52 (Pubitemid 11230828)
40. Bloch KJ, Buchanan WW, Wohl MJ, Bunim JJ. Sjoegren?s Syndrome. A Clinical, Pathological, and Serological Study of Sixty-Two Cases. Medicine (Baltimore) 1965;44:187-231
41. Skopouli FN, Barbatis C, Moutsopoulos HM. Liver involvement in primary Sjogren?s syndrome. Br J Rheumatol 1994;33: 745-8 (Pubitemid 24249182)
42. Lindgren S, Manthorpe R, Eriksson S. Autoimmune liver disease in patients with primary Sjogren?s syndrome. J Hepatol 1994;20:354-8 (Pubitemid 24082504)
43. Moutsopoulos HM. Sjogren?s syndrome: autoimmune epithelitis. Clin Immunol Immunopathol 1994;72:162-5
44. Selmi C, Meroni PL, Gershwin ME. Primary biliary cirrhosis and Sjogren?s syndrome: autoimmune epithelitis. J Autoimmun 2012;39:34-42
45. Allina J, Hu B, Sullivan DM, Fiel MI, Thung SN, Bronk SF, et al. T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis. J Autoimmun 2006;27:232-41 (Pubitemid 46199127)
46. Amador-Patarroyo MJ, Arbelaez JG, Mantilla RD, Rodriguez-Rodriguez A, Cardenas-Roldan J, Pineda-Tamayo R, et al. Sjogren?s syndrome at the crossroad of polyautoimmunity. J Autoimmun 2012;39:199-205
47. Bournia VK, Vlachoyiannopoulos PG. Subgroups of Sjogren syndrome patients according to serological profiles. J Autoimmun 2012;39:15-26
48. Hatzis GS, Fragoulis GE, Karatzaferis A, Delladetsima I, Barbatis C, Moutsopoulos HM. Prevalence and longterm course of primary biliary cirrhosis in primary Sjogren?s syndrome. J Rheumatol 2008;35:2012-6
49. Johnson SR, Fransen J, Khanna D, Baron M, van den Hoogen F, Medsger Jr TA, et al. Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res (Hoboken) 2012;64:358-67
50. D?Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). A study of fiftyeight autopsy cases and fifty-eight matched controls. Am J Med 1969;46:428-40
51. Hudson M, Rojas-Villarraga A, Coral-Alvarado P, Lopez-Guzman S, Mantilla RD, Chalem P, et al. Polyautoimmunity and familial autoimmunity in systemic sclerosis. J Autoimmun 2008;31:156-9
52. Imura-Kumada S, Hasegawa M, Matsushita T, Hamaguchi Y, Encabo S, Shums Z, et al. High prevalence of primary biliary cirrhosis and disease-associated autoantibodies in Japanese patients with systemic sclerosis. Mod Rheumatol 2012;22: 892-8
53. Assassi S, Fritzler MJ, Arnett FC, Norman GL, Shah KR, Gourh P, et al. Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients. J Rheumatol 2009;36:2250-6
54. Akiyama Y, Tanaka M, Takeishi M, Adachi D, Mimori A, Suzuki T. Clinical, serological and genetic study in patients with CREST syndrome. Intern Med 2000;39:451-6
55. Rigamonti C, Bogdanos DP, Mytilinaiou MG, Smyk DS, Rigopoulou EI, Burroughs AK. Primary biliary cirrhosis associated with systemic sclerosis: diagnostic and clinical challenges. Int J Rheumatol 2011;2011:976427
56. Rodrigues CE, Borges CL, de Carvalho JF. Diffuse systemic sclerosis and autoimmune hepatitis: a unique association. Clin Rheumatol 2010;29:799-801
57. Fraile G, Rodriguez-Garcia JL, Moreno A. Primary sclerosing cholangitis associated with systemic sclerosis. Postgrad Med J 1991;67:189-92
58. Lu Q. The critical importance of epigenetics in autoimmunity. J Autoimmun 2013;41:1-5
59. Hamdouch K, Rodriguez C, Perez-Venegas J, Rodriguez I, Astola A, Ortiz M, et al. Anti-CENPI autoantibodies in scleroderma patients with features of autoimmune liver diseases. Clin Chim Acta 2011;412:2267-71
60. Labirua-Iturburu A, Selva-O?Callaghan A, Vincze M, Danko K, Vencovsky J, Fisher B, et al. Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. Medicine (Baltimore) 2012;91:206-11
61. Ascherman DP. The role of Jo-1 in the immunopathogenesis of polymyositis: current hypotheses. Curr Rheumatol Rep 2003;5:425-30
62. Targoff IN. Autoantibodies and their significance in myositis. Curr Rheumatol Rep 2008;10:333-40
63. Mastaglia FL, Garlepp MJ, Phillips BA, Zilko PJ. Inflammatory myopathies: clinical, diagnostic and therapeutic aspects. Muscle Nerve 2003;27:407-25 (Pubitemid 36397059)
64. Kagen LJ, Aram S. Creatine kinase activity inhibitor in sera from patients with muscle disease. Arthritis Rheum 1987;30: 213-7 (Pubitemid 17060777)
65. Matsumoto T, Kobayashi S, Shimizu H, Nakajima M, Watanabe S, Kitami N, et al. The liver in collagen diseases: pathologic study of 160 cases with particular reference to hepatic arteritis, primary biliary cirrhosis, autoimmune hepatitis and nodular regenerative hyperplasia of the liver. Liver 2000;20:366-73
66. Hoffman M, Burke M, Fried M, Turner D, Yosipov Y, Yust I. Primary biliary cirrhosis associated with antiphospholipid syndrome. Isr J Med Sci. 1997;33:681-6 (Pubitemid 27499709)
67. Hua R,Wu H, Zhang XW, Sun YW. Probable catastrophic antiphospholipid syndrome complicated with primary sclerosing cholangitis. J Dig Dis 2012;13:601-3
68. Branger S, Schleinitz N, Veit V, Martaresche C, Bourliere M, Roblin X, et al. [Auto-immune hepatitis and antiphospholipids]. Rev Med Interne 2007;28:218-24
69. Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005;42:1194-202 (Pubitemid 43112687)
70. Takahashi A, Abe K, Yokokawa J, Iwadate H, Kobayashi H, Watanabe H, et al. Clinical features of liver dysfunction in collagen diseases. Hepatol Res. 2010;40:1092